• Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, 210006, China;
SunLihua, Email: nhfsun@sina.com
Export PDF Favorites Scan Get Citation

Objective To explore the effect of naringenin on the expression of vascular endothelial growth factor (VEGF) released by human fetal lung fibroblasts. Methods Human fetal lung fibroblast cells were divided into a control group,a cigarette smoke extract (CSE) group and a naringenin group. Cells in the naringenin group were incubated with different doses of naringenin for 2h. Then the naringenin group and the CSE group were incubated with CSE to adjust the final concentration of naringenin (5 μmol/L,10 μmol/L,and 20 μmol/L) and of CSE(5%). The concentration of VEGF was measured in human fetal lung fibroblasts after cultured for 24h,48h and 72h by enzyme-linked immunoabsorbent assay. Smad3 and p-Smad3 levels were detected by Western blot. Results ELISA results showed that the CSE can significantly increase the VEGF expression,and naringenin can inhibit the increasing of the VEGF expression. Western blot results showed that the CSE can increase the p-Smad3 expression,and the naringenin can inhibit the increasing of the p-Smad3 expression. Conclusion Naringenin can inhibit phosphorylation of Smad3,and decrease the expression of VEGF released by human fetal lung fibroblasts.

Citation: XuXiantao, SunLihua, ShiYing. The Effect of Naringenin on Vascular Endothelial Growth Factor Released by Human Fetal Lung Fibroblasts. Chinese Journal of Respiratory and Critical Care Medicine, 2014, 13(1): 18-20. doi: 10.7507/1671-6205.2014005 Copy

  • Previous Article

    Spectrum of Inflammatory Factors in Stable COPD Patients with Three Different Types of Body Mass Index
  • Next Article

    Medication Use in Asthmatic Patients in Communities of Putuo District Shanghai: A Cross-sectional Investigation